Filing Flows › TScan Therapeutics (TCRX) › Q4 2024
TScan Therapeutics (TCRX) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 5, 2025
TScan Therapeutics (TCRX) reported revenue of $665K for the fourth quarter 2024 (Q4 2024), -91% from a year earlier and -37% from the quarter before.
TScan Therapeutics, Q4 2024: revenue $665K (-91% year over year), net loss $35.8M, operating cash flow −$27.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $665K | -37% | -91% |
| Operating profit | −$36.7M | — | — |
| Net earnings | −$35.8M | — | — |
| Operating cash flow | −$27.4M | — | — |
What changed
Revenue was $665K in Q4 2024, down 91% year over year and down 37% from the previous quarter.
Operating costs exceeded revenue by $36.7M, an operating margin of -5520.6%. Total costs grew 31% against a revenue fall of 91%. The fastest-growing cost line was Research & development (+31%). The quarter ended with a net loss of $35.8M, wider than the previous quarter's $29.9M loss.
Operating cash flow was −$27.4M. Non-cash charges added back $711K of depreciation and $2.7M of share-based compensation. Working capital and other items added $5.0M. Capital expenditures of $888K exceeded it, leaving free cash flow of −$28.3M.
Questions
What was TScan Therapeutics' revenue in the fourth quarter 2024?
TScan Therapeutics (TCRX) reported revenue of $665K for the fourth quarter 2024 (Q4 2024), -91% from a year earlier and -37% from the quarter before.
Source: TScan Therapeutics 10-K on SEC EDGAR.